Our findings, therefore, define Kir2.1high/nN2ICDhigh as a biomarker for a highly malignant subtype of non-WNT/SHH MBs and suggest the Kir2.1-Notch2 pathway as a novel therapeutic target. This evidence concerns the gene KCNJ2 and Mobius syndrome.